Global systemic antibiotics market to reach $41.2 billion by 2018

Economic conditions and cost-containment issues have compelled North American and European antibiotic manufacturers to explore new regions, such as India, China and Brazil, for growth opportunities. However, a recent shift in the regulatory framework governing the antibiotics market is causing a positive impact on overall growth. An aging global population, regulatory measures, and patent expiries will shape modest growth in this market for at least the next five years.

BCC Research provides an in-depth analysis of the global systemic antibiotics market through its report, Antibiotics:Technologies and Global Markets. According to the report, this market was valued at  $39.3 billion in 2012 and $39.6 billion in 2013. BCC Research projects the market to grow to $41.2 billion by 2018, and register a five-year compound annual growth rate of 0.8% from 2013 to 2018.

RSS Feeds – Pharmaceuticals

Use this report to:

• Gain an overview of the global market for systemic antibiotics.
• Analyze global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
• Assess factors most impacting the market, including major market growth inhibitors and catalysts.
• Evaluate important trends and products.
• Review comprehensive profiles of leading companies in the industry.

SAMPLE FIGURE

GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2018

($ MILLIONS)

 

To order your copy of this report (or any of its chapters) or to download the complimentary introduction chapter, click here.


Please email us at reports@bccresearch.org if you have any questions pertaining to this report.

Antibiotic Resistance and Antibiotic Technologies: Global Markets

According to a new technical market research report, Antibiotic Resistance and Antibiotic Technologies: Global Markets (PHM025B) from BCC Research (www.bccresearch.com), the value of current antibiotics and new products in the global market is an estimated $41.5 billion in 2009, but is expected to increase to $65.5 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 9.6%.

The largest segment of the market, antibiotic drugs, is projected to grow at a CAGR of 5.9% to reach $50 billion in 2014. Its value is estimated at $37.6 billion in 2009.

Bacterial vaccines, the other segment of the market, is estimated at $3.9 billion in 2009, and is expected to increase at a 5-year CAGR of 31.6% to reach $15.5 billion in 2014.

Antibiotic resistance is a major health crisis throughout the world that requires an intensely focused action plan. Although resistance cannot be prevented, the problem is exacerbated by the fact that the pipeline targeting it is very lean, as the field was neglected by the industry for a long time.

The antibiotics sector is witnessing a new wave of interest in terms of investment, which is leading to innovation that was absent for more than two decades. The bacterial vaccines sector is expected to show particularly commendable growth trends during the 2009-2014 forecast period.

Regulatory trends emerging in various markets are expected to play key roles in the market growth. Because the best way to contain the resistance problem is to restrict the use of these products, it is expected to have a negative effect on the sector’s market growth. This is especially true for the established antibiotic classes that are facing serious resistance issues. Thus, the use of new classes of antibiotics will be encouraged, which will drive market growth.

This report is valuable reading for investors, policy makers, and industry participants.

Analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs.